Online inquiry

IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9852MR)

This product GTTS-WQ9852MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9852MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11273MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ14461MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ11076MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ6879MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ10196MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ5826MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ3487MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ2097MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW